iSpecimen Supports Hospital Validation of New Chemistry Analyzer
Newsfile Corp•29/09/2026•08:05 ET
0
Key Highlights
- ➤More than 1,700 specimens support hospital validation of new chemistry analyzer
- ➤Specimens span serum, plasma, CSF, and urine for analyzer testing
- ➤Hospital will complete validation before commencing clinical testing
- ➤iSpecimen (ISPC) coordinates ongoing collection between healthcare organizations
Expert Statements
Shahin Behroyan, Chief Executive Officer of iSpecimen
“Validating a new analyzer depends on access to the right specimens across a wide range of results.”
Shahin Behroyan, Chief Executive Officer of iSpecimen
“We're pleased to support this hospital by coordinating a collection that will help it bring new testing capabilities to its patients.”
Company coordinates collection of more than 1,700 human specimens to support new laboratory testing capabilities
Woburn, Massachusetts--(Newsfile Corp. - September 29, 2026) - iSpecimen, a provider of human biospecimens, is supporting a hospital laboratory in the validation of a new chemistry analyzer for clinical use. For the project, iSpecimen identified a healthcare system already using the same analyzer and is coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid (CSF), and urine specimens for use in the hospital's validation process.
Get started
Create a free account to read the full story.